Cramer’s Late-Stage Capitalism Play
If there’s one investing thesis that investors can always bank on, regardless of the economy, it’s this: It’s better to look good than feel good. Hence Cramer’s bullish sentiment toward stocks like Medicis Pharmaceutical .
This company for everything from acne medicines (Solodyn) to dermal fillers (Restylane, Perlane) to facial wrinkle treatments (Dysport), the last one being a direct competitor to Allergan’s well-known Botox. But in an attempt to elbow in on that territory, Medicis on March 1 launched the Dysport Challenge.
It’s a major promotion that offers customers a $75 rebate for their first Dysport treatment and another $75 for a second one. Or, if they’re unsatisfied, they can spend it on Botox instead. Most of them haven’t, though, with just 2.5% of the 100,000 registered patients deciding to leave the challenge. Cramer also noted that Medicis has done a great job of winning over doctors, which is crucial to their success.
The stock is up 17% since the Dysport Challenge began, compared to the S&P 500’s 4% loss over the same period. To hear more about Medicis’ prospects, as well as its strong quarter reported Aug. 5, Cramer invited CEO John Shacknai to the show. Watch the video for the full interview.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org